<noframes id="7dr1n">

<noframes id="7dr1n">
<form id="7dr1n"></form>
      ?

      产品搜索:

      手机:18001401806;18915562593

      电话: 0517-86993111;0512-62729923

      传真: 0512-62729923

      联系人: 贾经理;胡总

      邮编: 215000

      地址: 江苏省苏州市工业园区仁爱路150号C316室

      当前位置>>返回首页

      Chinese Name

      中文名


       酚维A胺

      English Name

      英文名


      Fenretinide

      Alias

      别名


      (4-Hydroxyphenyl)retinamide; 4-HPR; Fenretinide; N-(4-Hydroxyphenyl)-all-trans-retinamide;N-(4-Hydroxyphenyl)retinamide; RII retinamide; Retinoic acid p-hydroxyphenylamide; Ro22-4667; all-trans-4'-Hydroxyretinanilide; all-trans-N-(4-Hydroxyphenyl)retinamide


      CAS NO.


      65646-68-6

      Formula

      分子式


      C26H33NO2

      M.W.

      分子量


      391.55

      Class

      分类


      原料药



      酚维A胺(4.HPR)于20世纪70年代由强生公司研发的,属于维甲酸类化合物,有显著的肿瘤化学预防作用。随着研究的深入,发现4.HPR与传统的维甲酸类化合物不同,其诱导分化作用较弱,而促进肿瘤细胞凋亡较强,且毒性远较其它维甲酸类化合物低,可长期使用,耐药性发生率也较传统维甲酸类化合物低,并可单独或合用其它化疗药物抗肿瘤。近年来的研究显示4-HPR对多种实体瘤均有直接的抑制作用并已进入了临床试验。4-HPR能够抑制肿瘤细胞增殖、促进分化、引发凋亡,并影响其他信号传导途径‘91。4-HPR诱导凋亡的生化途径十分复杂,己报道同时有维甲酸(RA)受体依赖型和RA受体非依赖型,后者包括促进活性氧簇(RO)s及神经酰胺的产生等。因此4-HPR成为目前研究的热点之一。

      [1]Paik J,Vogel S,Pinatedosi R,et a1.9-cis—retinoids:Biosynthesis of9-cis—retinoicacid[J].Biochemistry,2000,39(27):8073-8084.
      [2]靳培英,徐文严。异维A酸在皮肤病治疗领域中的临床应用[J]。国外医学皮肤性病学分册,1998,24(2):65.68。
      [3]Sangmam C,Winum J YA simple,general and efficient method for O andN-retinoylation application to the synthesis of 2-retinoyl-Lecithin[J].SnythetieCommuniactions,1998,28(16):2945-958.
      [4]Zhang X K,Liu Y Lee M O.Retinoid receptors in human lung cancer and breastCancer[J].Mutation Researeh,1 996,350:267-277.
      [5]Petkovich M,Brand N J,K.rust A,et a1.A human retinoic acid receptor whichbelongs to the family of nuclear rec印tors[J].Nature,l 987,330:444.450.
      [6]Gigueer V Onf S,Seugi P,et a1.Identifiaction of receptor of the morphogenretinoid acid[J].Nature,1 987,330:624-629.
      [7]N iles R M.Recent advances in the use of Vitamin A(retinoids)in the preventionand treatment of cancer[J].Nutrition,2000,l 6(1 1.1 2):l 084.1 090.
      [8]Napgal S,Roshantha A S.Recent developments in receptor-selective retinoids[J].Current Pharmaceutical Design,2000.6:9 1 9?93 1.
      [9]Laudet V Gronemeyer H.The nuclear receptor factsbook[R].Academic Press,SanDiego,CA,2002.
      [10]Hiroyuki K,Koichi S.Synthetic retinoids:recent developments concerningctructure and clinical utility[J].J.Med.Chem.,2005,48(19),5875.5883.
      [1l]Maglich J M,SluderA,et a1.Comparison ofcomplete nuclear receptor sets fromthe human.Caenorhabditis elegans and Drosophila genomes[J].Genome Biol,200 1,2(1).
      [12]Sporn M B,RobeasAB.What is a retinoid?Ciba Found[J].Symp,1985,113:1-5.
      [13]Cunlifie W J,Miller A J,et a1.Retinoid Therapy:A review of Clinical andlaboratory research[G].MTP Press Limited:Lancaster,1 984.
      [14]Kagechika H.Therapeutic application of synthetic retinoids[J].I Drugs 2000,3:73.83.
      [15]Ellis C N,Voorhees J J,Etretinate therapy[J].J Am Acad Dermatol,1 987,1 6:267.291.
      [16]Heyman R A,Mangelsdorf D J,et a1.9-Cis retinoic acid is a high affinity ligand for the retinoid X receptor[J].Cell,1 992,68:397—406.
      [17]Zhang X?K,Lehmann J,et a1.Homodimer formation of retinoid X receptor induced by 9-cis retinoic acid[J]。Nature,1992,358:587-591.
      [18]Forman M.,Umesono K,et a1.Unique response pathways are established by allosteric interactions among nuclear hormone rec印tors[J].Cell,1 995,8 1:54 1.550.
      [19]Kurokawa R.,Soderstrom M,et a1.Polatiry.specific activities of retinoic acid receptors determined by a co—repressor[J].Nature,1995,377:451-454.
      [20]Vivat V Zechel C,et a1.A mutation mimicking the ligand—induced conformational change yields a constitutive RXR that senses allosteric effects inheterodimers[J].EMBO J,1 997,1 6:5697.5709.
      [21]郝北辰,张奕华。具有抗肿瘤作用的维甲酸类化合物的研究进展[J]。药学进展,2006,30(2),65.68.
      [22]Chawala A.,Repa J.J.,et a1.Nuclear receptors and lipid physiology:Opening the X-files[J].Science 2001,294:1 866-1 870.
      [23]Lucia A,Mark D,et a1.RAR and RXR modulation in cancer and metabolic disease[J].Nature Publishing Group,2007(6):793—8 1 0.
      [24]Kagechika H.Novel synthetic retinoids and separation of the pleiotropic retinoidal activities[J].Curr.Med.Chem.2002,9:591.608.
      [25]Yamakawa T,Kagechika H,et a1.Retinoidal activities of compounds having a trimethylsilyl or trimethylgermyl group(s)in human promyelocytic leukemia cells HL一60[J].J Med Chem,1990,33:1430.1437.
      [26]Teng M,Duong T,et a1.Identification of a retinoic acid receptor R subtype specific agonist[J]-J Med Chem,l 996,39:3035.3038.
      [27]Bourguet W,Germain P,Gronemeyer H.Nuclear receptor ligand.Binding domains:three—dimensional structures,molecular interactions and pharmacological implications[J].Trends Pharmacol Sci.2000,2l:381-388.






































      ?

      地址: 江苏省苏州市工业园区仁爱路150号C316室 电话:0517-86993111;0512-62729923

      版权所有:苏州东南药业股份有限公司 备案号:<a href="http://beian.miit.gov.cn" target="_blank">苏ICP备19046012号-1</a> 技术支持:苏州开创网络

      水果机 <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <文本链> <文本链> <文本链> <文本链> <文本链> <文本链>